ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options

For Merck & Co., the oncology show has been all about Keytruda but also about Lynparza and Lenvima for the past few years. But the New Jersey pharma is hoping to soon have some supporting players to add to the playbill.

“I think sometimes people don't appreciate the breadth of our pipeline beyond Keytruda,” said Eric Rubin, Ph.D., senior vice president of early-stage development, clinical oncology, at Merck Research Laboratories.